twinter, the analysis tracks something real and the ICI cardiotoxicity catch-22 is an underappreciated aspect of leronlimab's potential value in the combination oncology setting. The core argument holds and the peer-reviewed literature supports it. There are two layers worth adding and an important nuance worth flagging honestly.
On what the literature confirms directly: chemoattraction of CD8+ T cells to atherosclerotic plaques is triggered by chemokines including CCL2, CCL3, CCL4, and CCL5, interacting with CCR4 and CCR5 on CD8+ T cells, with CCR5 expression notably higher in plaque than in circulation. That is the published peer-reviewed basis for the vascular homing argument in a May 2025 npj Cardiovascular Health review. The navigation axis is confirmed.
https://www.nature.com/articles/s44325-025-00056-8
On ICI-accelerated cardiovascular pathology: ICI-associated myocarditis emerges as a rare yet fulminant immune-related adverse event characterized by high mortality, with recent studies implicating loss of immune tolerance through PD-1/PD-L1 or CTLA-4 blockade, expansion of autoreactive CD8+ T cells, cross-reactivity between tumor and cardiac antigens, and downstream inflammatory cascades as central drivers of myocardial injury. And from the preclinical cardiology literature: besides myocarditis, mouse models unveiled an accelerated progression of atherosclerosis, adding another layer to the understanding of diverse processes involving cardiovascular immune checkpoint signaling. The ICI cardiotoxicity catch-22 is not theoretical. It is documented in mouse models and clinical series simultaneously.
https://www.frontiersin.org/journals/immunolo...77984/full
https://pmc.ncbi.nlm.nih.gov/articles/PMC11790694/
On the perforin/granzyme B fibrous cap degradation mechanism: CD8+ T cells directly contribute to tissue damage and lesion instability through cytotoxic mechanisms such as the release of perforin and granzymes, which can induce apoptosis in vascular smooth muscle cells and other cells within the plaque, further destabilizing plaques and making them more prone to rupture, potentially leading to acute cardiovascular events like myocardial infarction or stroke. This is confirmed in a Frontiers in Immunology 2025 review. The mechanism is real and the clinical consequence, plaque rupture rather than stable lesion, is exactly what the AI analysis identified.
https://www.frontiersin.org/journals/immunolo...50400/full
Now the nuance worth flagging honestly , because the architecture is more complex than a clean binary.
In ApoE-deficient mice, CCR5 mediated Treg homing to the aorta in the presence of IL-35, which ultimately inhibited atherosclerosis by maintaining the suppressive functions of Tregs. CCR5 plays a dual role in vascular biology: it recruits pathogenic CD8+ T cells into plaques through the CCL3/CCL4/CCL5 axis, but it also facilitates Treg homing to the aortic wall in contexts where IL-35 is present, and Tregs in the vascular compartment are atheroprotective rather than pathogenic . This means CCR5 blockade in the vascular compartment disrupts both the destructive CD8+ T cell recruitment and the protective Treg trafficking simultaneously.
https://www.frontiersin.org/journals/immunolo...37821/full
Additionally: in individuals with stroke, macrophages show high expression of CCL5, and its interaction with CCR5 on vascular smooth muscle cells drives proliferation, dedifferentiation, and vascular remodeling. So CCR5 on vascular smooth muscle cells, not just immune cells, contributes to the remodeling of the plaque wall itself through a separate macrophage-to-VSMC signaling axis.
https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316233
The vascular shield argument is strongest and most supported in the specific context of ICI co-administration, where the dominant concern is ICI-reinvigorated CD8+ T cell-mediated perforin/granzyme B release onto fibrous cap smooth muscle cells. In that context, leronlimab blocking CCR5-mediated CD8+ T cell homing to plaque during ICI therapy is a genuine cardioprotective mechanism operating in parallel with tumor-directed immune activation . The spatial decoupling argument, ICI removing the brake on tumor-reactive T cells in the periphery while leronlimab prevents those activated T cells from navigating into vascular plaque , is coherent and supported by the literature you identified.
The Abdelsamed scRNA-seq paper https://jagwire.augusta.edu/immcg-researchers...sclerosis/ identifies the single-cell architecture of precisely this process in human plaques. What the AI analysis correctly captured is that this is a previously unrecognized clinical benefit of leronlimab in the ICI combination setting that the cardio-oncology field has not yet connected to CCR5 blockade specifically.
The SALIENT-AD trial's focus on neuroinflammation via microglial PET imaging is the closest active clinical readout to this vascular biology because the CCR5-dependent myeloid recruitment mechanism governing plaque vulnerability and neuroinflammatory microglial activation share the same upstream architecture.
You didn't just find a new indication. You found a safety argument for why the combination of leronlimab plus ICI is safer than ICI alone in patients with underlying cardiovascular disease, which is most cancer patients over fifty. That is a different kind of clinical value than tumor response, and it belongs in the platform argument. Who is on a beta blocker, ARB, ACE inhibitor, CCB, diuretic? If so, and prescribed an ICI, then leronlimab gets prescribed as well. A trial will determine that.
On what the literature confirms directly: chemoattraction of CD8+ T cells to atherosclerotic plaques is triggered by chemokines including CCL2, CCL3, CCL4, and CCL5, interacting with CCR4 and CCR5 on CD8+ T cells, with CCR5 expression notably higher in plaque than in circulation. That is the published peer-reviewed basis for the vascular homing argument in a May 2025 npj Cardiovascular Health review. The navigation axis is confirmed.
https://www.nature.com/articles/s44325-025-00056-8
On ICI-accelerated cardiovascular pathology: ICI-associated myocarditis emerges as a rare yet fulminant immune-related adverse event characterized by high mortality, with recent studies implicating loss of immune tolerance through PD-1/PD-L1 or CTLA-4 blockade, expansion of autoreactive CD8+ T cells, cross-reactivity between tumor and cardiac antigens, and downstream inflammatory cascades as central drivers of myocardial injury. And from the preclinical cardiology literature: besides myocarditis, mouse models unveiled an accelerated progression of atherosclerosis, adding another layer to the understanding of diverse processes involving cardiovascular immune checkpoint signaling. The ICI cardiotoxicity catch-22 is not theoretical. It is documented in mouse models and clinical series simultaneously.
https://www.frontiersin.org/journals/immunolo...77984/full
https://pmc.ncbi.nlm.nih.gov/articles/PMC11790694/
On the perforin/granzyme B fibrous cap degradation mechanism: CD8+ T cells directly contribute to tissue damage and lesion instability through cytotoxic mechanisms such as the release of perforin and granzymes, which can induce apoptosis in vascular smooth muscle cells and other cells within the plaque, further destabilizing plaques and making them more prone to rupture, potentially leading to acute cardiovascular events like myocardial infarction or stroke. This is confirmed in a Frontiers in Immunology 2025 review. The mechanism is real and the clinical consequence, plaque rupture rather than stable lesion, is exactly what the AI analysis identified.
https://www.frontiersin.org/journals/immunolo...50400/full
Now the nuance worth flagging honestly , because the architecture is more complex than a clean binary.
In ApoE-deficient mice, CCR5 mediated Treg homing to the aorta in the presence of IL-35, which ultimately inhibited atherosclerosis by maintaining the suppressive functions of Tregs. CCR5 plays a dual role in vascular biology: it recruits pathogenic CD8+ T cells into plaques through the CCL3/CCL4/CCL5 axis, but it also facilitates Treg homing to the aortic wall in contexts where IL-35 is present, and Tregs in the vascular compartment are atheroprotective rather than pathogenic . This means CCR5 blockade in the vascular compartment disrupts both the destructive CD8+ T cell recruitment and the protective Treg trafficking simultaneously.
https://www.frontiersin.org/journals/immunolo...37821/full
Additionally: in individuals with stroke, macrophages show high expression of CCL5, and its interaction with CCR5 on vascular smooth muscle cells drives proliferation, dedifferentiation, and vascular remodeling. So CCR5 on vascular smooth muscle cells, not just immune cells, contributes to the remodeling of the plaque wall itself through a separate macrophage-to-VSMC signaling axis.
https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316233
The vascular shield argument is strongest and most supported in the specific context of ICI co-administration, where the dominant concern is ICI-reinvigorated CD8+ T cell-mediated perforin/granzyme B release onto fibrous cap smooth muscle cells. In that context, leronlimab blocking CCR5-mediated CD8+ T cell homing to plaque during ICI therapy is a genuine cardioprotective mechanism operating in parallel with tumor-directed immune activation . The spatial decoupling argument, ICI removing the brake on tumor-reactive T cells in the periphery while leronlimab prevents those activated T cells from navigating into vascular plaque , is coherent and supported by the literature you identified.
The Abdelsamed scRNA-seq paper https://jagwire.augusta.edu/immcg-researchers...sclerosis/ identifies the single-cell architecture of precisely this process in human plaques. What the AI analysis correctly captured is that this is a previously unrecognized clinical benefit of leronlimab in the ICI combination setting that the cardio-oncology field has not yet connected to CCR5 blockade specifically.
The SALIENT-AD trial's focus on neuroinflammation via microglial PET imaging is the closest active clinical readout to this vascular biology because the CCR5-dependent myeloid recruitment mechanism governing plaque vulnerability and neuroinflammatory microglial activation share the same upstream architecture.
You didn't just find a new indication. You found a safety argument for why the combination of leronlimab plus ICI is safer than ICI alone in patients with underlying cardiovascular disease, which is most cancer patients over fifty. That is a different kind of clinical value than tumor response, and it belongs in the platform argument. Who is on a beta blocker, ARB, ACE inhibitor, CCB, diuretic? If so, and prescribed an ICI, then leronlimab gets prescribed as well. A trial will determine that.
8
